ORTX earnings

-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acquisition enriches Kyowa Kirin's portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy® (atidarsagene autotemcel)--Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a total maximum equity value of approximately $477.6 million--Kyowa Kirin to host investor conference call on Oct 5 at 18:30 p.m. JST- TOKYO and LONDON and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Ky

Reported $6.6M in Q2'23 Libmeldy net sales, representing the highest quarter to date $34.0M of additional capital from second closing of strategic financing extends runway to mid-2025 Four MLD patients identified from ~150,000 newborns screened in prospective studies suggests significantly higher incidence than previously estimated in the medical literature Six presentations at ASGCT demonstrate the ability of HSC gene therapy to address neurometabolic and CNS disorders, as well as larger indications Company to host conference call and live webcast today at 8:00 a.m. EDT BOSTON and LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene th

BOSTON and LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, August 3, 2023, at 8:00 a.m. EDT to review business updates and its second quarter 2023 financial results. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. Analysts wishing to participate in the question and answer session should use this link to register. A replay of the webcast will be archived on the Orchard website following the presentation. About Orchard TherapeuticsAt Orchard Therapeutics,

New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates, improvement in joint function and progressive acquisition of motor skills Updated OTL-201 data from ongoing proof-of-concept study in MPS-IIIA patients show additional favorable neurocognitive outcomes compared to disease natural history with median follow-up of 2.5 years First preclinical data for OTL-204 highlight ability of HSC gene therapy to restore microglial function, modulate neuroinflammation, and normalize predictive biomarkers in the progranulin form of frontotemporal dementia (GRN-FTD) Company to host conference call and web

Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn's disease, a severe and treatment-refractory form of the disease In vivo data demonstrate the development of CAR-Treg cells from genetically engineered HSCs as a potential one-time treatment for autoimmune disorders Company to host conference call and webcast Tuesday, May 23 at 8:00 a.m. EDT BOSTON and LONDON, May 18, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today presented new data from the company's hematopoietic stem cell (HSC) gene therapy research pipeline targeting larger indications at the ongoing 26th Annual Meeting of the American Society

OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA) Strategic financing from leading healthcare investors provides up to $188 million of additional capital upon achievement of key milestones $18.8M of Libmeldy revenue in 2022 with growth expected in 2023 from ongoing commercial expansion activities in Europe Newborn screening studies have confirmed three cases of metachromatic leukodystrophy (MLD) with 96,000 babies screened globally to date Company to webcast conference call today at 8:00 a.m. ET BOSTON and LONDON, March 06, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX)

All patients achieved sustained engraftment and supraphysiological SGSH enzyme levels with median 1.5 years follow-up Four out of five patients demonstrated gain of cognitive skills in line with development in healthy children with one patient showing a marked improvement compared to disease natural history Treatment with OTL-201 was generally well-tolerated Company to host conference call and webcast at 5:00 p.m. EST BOSTON and LONDON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced early clinical findings, including the first neurocognitive results, from its ongoing proof-of-concept (PoC) study of OTL-201, an

BOSTON and LONDON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Monday, November 14, 2022, at 8:00 a.m. EST to review business updates and its third quarter 2022 financial results. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. The conference call can be accessed by dialing (800) 715-9871 (toll-free) or (646) 307-1963 (toll) and using the conference ID 8411062. A replay of the webcast will be archived on the Orchard website following the presentation. About Orchard T

Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy® access and reimbursement expanding with agreements now signed in three major European markets recognizing its clinical value OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven upcoming presentations at ASGCT highlight application of HSC approach including clinical and research programs Cash and investments of approximately $200M provide runway into 2024 BOSTON and LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced recent business highlights along with its financial results for the qua

BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022, at 8:00 a.m. ET to review business updates and its first quarter 2022 financial results. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. The conference call can be accessed by dialing +1 (866) 374-5140 (toll-free) or +1 (404) 400-0571 (toll) and using the passcode 71474312. A replay of the webcast will be archived on the Orchard website following the presentation. About Orchard

Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of OTL-200 on track for late 2022 / early 2023 Broad research platform presents opportunities for larger indications and partnerships; preclinical POC data in NOD2 Crohn's disease expected by year end and IND filing planned in 2024 Plan to seek strategic alternatives for primary immunodeficiency programs, including OTL-103 in WAS Refined portfolio and 30% proposed workforce reduction extend cash runway into 2024 BOSTON and LONDON, March 30, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced it

BOSTON and LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Wednesday, March 30, 2022, at 8:00 a.m. ET to review business updates and its fourth quarter and fiscal year 2021 financial results. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. The conference call can be accessed by dialing (866) 987-6504 (U.S. domestic) or +1 (602) 563-8620 (international) and referring to conference ID 9445456. A replay of the webcast will be archived on the Orchard website followin